• Age 18 Years to 75 Years years
• Newly diagnosed, not yet treated
• Must be well enough for treatment (adequate performance status)

CD70 CAR-NK (BIOLOGICAL): CAR - NK cells constructed by using genetic engineering technology retain the original extensive tumor - killing ability of NK cells. By using their unique target cell recognition mechanism, the target is accurately locked on specific antigen proteins, thereby enhancing the anti - tumor effect. Cord blood-derived CAR - NK cell products shorten the treatment time and are inexpensive. Multiple studies have confirmed the feasibility of CAR - NK cells in treating hematological tumors. Blocking the CD70/CD27 signaling pathway plays an important role in inhibiting CD70 - positive tumors, such as refractory/relapsed T - cell lymphoma and acute myeloid leukemia. Pre - clinical studies in our laboratory have proved that CD70 CAR - NK can effectively inhibit the in - vivo and in - vitro proliferation of T - cell lymphoma and prolong survival.

Drugs / treatments: CD70 CAR-NK

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Non-randomized, open-label

Enrollment target: 25 patients

Primary endpoint: The incidence and type of dose-limiting toxicity (DLT) within 28 days; the incidence and severity of treatment-related adverse events as assessed by CTCAE v4.0

Ages: 18 Years to 75 Years

Start date: 2024-12-01 | Est. completion: 2028-11-30

0 US sites · 1 total

Wenbin Qian | qianwb@zju.edu.cn | +86 0571 87783759

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University (OTHER)

AITL/TFH · ALCL ALK− · Maintenance · Newly diagnosed · Relapsed/Refractory

https://clinicaltrials.gov/study/NCT06696846